Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial
Table 6
The proportion of ICS responders to Gag or Env peptide pools two weeks after the first and second HIV-MVA vaccination in each of the HIV-DNA primed groups.